344 related articles for article (PubMed ID: 34654875)
1. Sulforaphane ameliorates non-alcoholic fatty liver disease in mice by promoting FGF21/FGFR1 signaling pathway.
Wu YK; Ren ZN; Zhu SL; Wu YZ; Wang G; Zhang H; Chen W; He Z; Ye XL; Zhai QX
Acta Pharmacol Sin; 2022 Jun; 43(6):1473-1483. PubMed ID: 34654875
[TBL] [Abstract][Full Text] [Related]
2. Hepatocyte-specific fibroblast growth factor 21 overexpression ameliorates high-fat diet-induced obesity and liver steatosis in mice.
Yano K; Yamaguchi K; Seko Y; Okishio S; Ishiba H; Tochiki N; Takahashi A; Kataoka S; Okuda K; Liu Y; Fujii H; Umemura A; Moriguchi M; Okanoue T; Itoh Y
Lab Invest; 2022 Mar; 102(3):281-289. PubMed ID: 34732847
[TBL] [Abstract][Full Text] [Related]
3.
Long X; Liu D; Gao Q; Ni J; Qian L; Ni Y; Fang Q; Jia W; Li H
Front Endocrinol (Lausanne); 2021; 12():773340. PubMed ID: 35035378
[TBL] [Abstract][Full Text] [Related]
4. MicroRNA-376b-3p ameliorates nonalcoholic fatty liver disease by targeting FGFR1 and regulating lipid oxidation in hepatocytes.
Wang XY; Lu LJ; Li YM; Xu CF
Life Sci; 2022 Nov; 308():120925. PubMed ID: 36057399
[TBL] [Abstract][Full Text] [Related]
5. Artemisia scoparia extract attenuates non-alcoholic fatty liver disease in diet-induced obesity mice by enhancing hepatic insulin and AMPK signaling independently of FGF21 pathway.
Wang ZQ; Zhang XH; Yu Y; Tipton RC; Raskin I; Ribnicky D; Johnson W; Cefalu WT
Metabolism; 2013 Sep; 62(9):1239-49. PubMed ID: 23702383
[TBL] [Abstract][Full Text] [Related]
6. Sulforaphane Regulates Glucose and Lipid Metabolisms in Obese Mice by Restraining JNK and Activating Insulin and FGF21 Signal Pathways.
Tian S; Wang Y; Li X; Liu J; Wang J; Lu Y
J Agric Food Chem; 2021 Nov; 69(44):13066-13079. PubMed ID: 34706542
[TBL] [Abstract][Full Text] [Related]
7. Hepatic STAMP2 mediates recombinant FGF21-induced improvement of hepatic iron overload in nonalcoholic fatty liver disease.
Kim HY; Kwon WY; Park JB; Lee MH; Oh YJ; Suh S; Baek YH; Jeong JS; Yoo YH
FASEB J; 2020 Sep; 34(9):12354-12366. PubMed ID: 32721044
[TBL] [Abstract][Full Text] [Related]
8. Fibroblast growth factor 21 is required for the therapeutic effects of Lactobacillus rhamnosus GG against fructose-induced fatty liver in mice.
Zhao C; Liu L; Liu Q; Li F; Zhang L; Zhu F; Shao T; Barve S; Chen Y; Li X; McClain CJ; Feng W
Mol Metab; 2019 Nov; 29():145-157. PubMed ID: 31668386
[TBL] [Abstract][Full Text] [Related]
9. Spinal Cord Injury Reduces Serum Levels of Fibroblast Growth Factor-21 and Impairs Its Signaling Pathways in Liver and Adipose Tissue in Mice.
Liu XH; Graham ZA; Harlow L; Pan J; Azulai D; Bauman WA; Yarrow J; Cardozo CP
Front Endocrinol (Lausanne); 2021; 12():668984. PubMed ID: 34046014
[TBL] [Abstract][Full Text] [Related]
10. Psoralea corylifolia L. extract ameliorates nonalcoholic fatty liver disease in free-fatty-acid-incubated HEPG2 cells and in high-fat diet-fed mice.
Hong Y; Choi SI; Hong E; Kim GH
J Food Sci; 2020 Jul; 85(7):2216-2226. PubMed ID: 32579753
[TBL] [Abstract][Full Text] [Related]
11. Albumin-fused long-acting FGF21 analogue for the treatment of non-alcoholic fatty liver disease.
Chikamatsu M; Watanabe H; Shintani Y; Murata R; Miyahisa M; Nishinoiri A; Imafuku T; Takano M; Arimura N; Yamada K; Kamimura M; Mukai B; Satoh T; Maeda H; Maruyama T
J Control Release; 2023 Mar; 355():42-53. PubMed ID: 36690035
[TBL] [Abstract][Full Text] [Related]
12. Alcoholic fatty liver is blunted by rFGF21 administration in mice lacking adipose FGFR1: The role of FGF21 in PPARα-mediated regulation of adipose tissue mass.
Xu Y; Lu Y
Biochem Biophys Res Commun; 2022 Sep; 619():84-89. PubMed ID: 35749940
[TBL] [Abstract][Full Text] [Related]
13. Macrophage-specific FGFR1 deletion alleviates high-fat-diet-induced liver inflammation by inhibiting the MAPKs/TNF pathways.
Zhao YN; Liu ZD; Yan T; Xu TX; Jin TY; Jiang YS; Zuo W; Lee KY; Huang LJ; Wang Y
Acta Pharmacol Sin; 2024 May; 45(5):988-1001. PubMed ID: 38279043
[TBL] [Abstract][Full Text] [Related]
14. Alternate-day fasting alleviates high fat diet induced non-alcoholic fatty liver disease through controlling PPARα/Fgf21 signaling.
Liu X; Zhang Y; Ma C; Lin J; Du J
Mol Biol Rep; 2022 Apr; 49(4):3113-3122. PubMed ID: 35107741
[TBL] [Abstract][Full Text] [Related]
15. Procyanidin B2 ameliorates free fatty acids-induced hepatic steatosis through regulating TFEB-mediated lysosomal pathway and redox state.
Su H; Li Y; Hu D; Xie L; Ke H; Zheng X; Chen W
Free Radic Biol Med; 2018 Oct; 126():269-286. PubMed ID: 30142454
[TBL] [Abstract][Full Text] [Related]
16. Modulation of endoplasmic reticulum stress via sulforaphane-mediated AMPK upregulation against nonalcoholic fatty liver disease in rats.
Mansour SZ; Moustafa EM; Moawed FSM
Cell Stress Chaperones; 2022 Sep; 27(5):499-511. PubMed ID: 35779187
[TBL] [Abstract][Full Text] [Related]
17. Mesencephalic astrocyte-derived neurotrophic factor ameliorates steatosis in HepG2 cells by regulating hepatic lipid metabolism.
He M; Wang C; Long XH; Peng JJ; Liu DF; Yang GY; Jensen MD; Zhang LL
World J Gastroenterol; 2020 Mar; 26(10):1029-1041. PubMed ID: 32205994
[TBL] [Abstract][Full Text] [Related]
18. A Fibroblast Growth Factor 21-Pregnane X Receptor Pathway Downregulates Hepatic CYP3A4 in Nonalcoholic Fatty Liver Disease.
Woolsey SJ; Beaton MD; Mansell SE; Leon-Ponte M; Yu J; Pin CL; Adams PC; Kim RB; Tirona RG
Mol Pharmacol; 2016 Oct; 90(4):437-46. PubMed ID: 27482056
[TBL] [Abstract][Full Text] [Related]
19. Antrodia cinnamomea and its compound dehydroeburicoic acid attenuate nonalcoholic fatty liver disease by upregulating ALDH2 activity.
Cao YN; Yue SS; Wang AY; Xu L; Hu YT; Qiao X; Wu TY; Ye M; Wu YC; Qi R
J Ethnopharmacol; 2022 Jun; 292():115146. PubMed ID: 35304272
[TBL] [Abstract][Full Text] [Related]
20. Lycopus lucidus Turcz. ex Benth. Attenuates free fatty acid-induced steatosis in HepG2 cells and non-alcoholic fatty liver disease in high-fat diet-induced obese mice.
Lee MR; Yang HJ; Park KI; Ma JY
Phytomedicine; 2019 Mar; 55():14-22. PubMed ID: 30668424
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
